Mesoblast (MEOBF) Short-term Investments (2015 - 2016)
Mesoblast's (MEOBF) quarterly Short-term Investments came in at -$805000.0 in Q2 2016, little changed quarter-over-quarter from -$805000.0 in Q1 2016.
Powered by 
Analysis
Mesoblast (MEOBF) Short-term Investments (2015 - 2016) Analysis & Trends
Mesoblast has disclosed Short-term Investments across 2 years of filings, most recently posting -$805000.0 for Q2 2016.
- In Q2 2016, Short-term Investments changed N/A year-over-year to -$805000.0; the TTM figure through Jun 2016 stood at -$805000.0 (changed N/A YoY), while the FY2016 annual figure was -$805000.0, changed N/A from the prior year.
- Short-term Investments came in at -$805000.0 for Q2 2016 at Mesoblast, roughly flat from -$805000.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of -$585134.0 in Q3 2015 to a low of -$805000.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2016 | -805,000.00 |
| Mar 31, 2016 | -805,000.00 |
| Dec 31, 2015 | -805,000.00 |
| Sep 30, 2015 | -585,134.03 |